本文選題：酪氨酸激酶抑制劑 + 晚期腎癌��； 參考：《重慶醫(yī)科大學(xué)》2014年碩士論文

【摘要】：腎癌是來源于腎實質(zhì)泌尿小管上皮系統(tǒng)的惡性腫瘤,是泌尿系統(tǒng)的常見病和高發(fā)病，在人類惡性腫瘤中腎癌的發(fā)病率占有很高的比重,約占成人惡性腫瘤的2%～3%，占成人腎臟惡性腫瘤的80%～90%。腎臟豐富的血供決定了腎癌的早期高轉(zhuǎn)移性，，約25%的腎癌病人存在腫瘤轉(zhuǎn)移,很大一部分患者在初診時即發(fā)現(xiàn)腫瘤轉(zhuǎn)移，統(tǒng)計資料顯示，死于腎癌的患者數(shù)目逐年增加。故而晚期腎癌的治療對于患者的預(yù)后及生存質(zhì)量提高均具有重要意義，近年來，隨著對腎癌生物學(xué)及分子發(fā)病機(jī)制的深入了解,尤其是分子信號通路方面研究的不斷深入,靶向治療在晚期腎癌治療方面已顯現(xiàn)出明顯優(yōu)勢，其中各種酪氨酸激酶抑制劑更是廣泛的應(yīng)用于臨床上腎癌的治療，有效地改善了晚期腎癌患者的預(yù)后。酪氨酸激酶抑制劑是一種酶受體蛋白，它可以催化腺嘌呤核苷三磷酸里面的磷酸鹽向多肽里面的酪氨酸轉(zhuǎn)運(yùn)，從而有效的抑制腫瘤的增殖、血管生成和侵襲。本文將對酪氨酸激酶抑制劑治療晚期腎癌的治療原理，各種酪氨酸激酶抑制劑的治療晚期腎癌的治療效果和安全性進(jìn)行闡述，探討酪氨酸激酶抑制劑治療晚期腎癌的研究現(xiàn)狀，從而更好的幫助臨床醫(yī)生制定治療方案。
[Abstract]:Renal cell carcinoma is a malignant tumor derived from the renal parenchymal urothelial system. It is a common and high incidence disease of the urinary system. It accounts for 2% of adult malignant tumors and 80% of adult renal malignancies. The abundant blood supply of kidney determines the early high metastasis of renal cell carcinoma. About 25% of renal cancer patients have tumor metastasis. A large number of patients found tumor metastasis at the first visit. Statistics show that the number of patients who died of renal carcinoma increased year by year. Therefore, the treatment of advanced renal cell carcinoma plays an important role in improving the prognosis and quality of life of patients. In recent years, with the in-depth understanding of the biology and molecular pathogenesis of renal cell carcinoma, especially the study of molecular signal pathway, Targeted therapy has shown obvious advantages in the treatment of advanced renal cell carcinoma, among which various tyrosine kinase inhibitors have been widely used in clinical treatment of renal cell carcinoma, which can effectively improve the prognosis of patients with advanced renal cell carcinoma. Tyrosine kinase inhibitor is an enzyme receptor protein that catalyzes the transport of phosphate from adenosine triphosphate to tyrosine in polypeptides, which effectively inhibits tumor proliferation, angiogenesis and invasion. In this paper, the principle of tyrosine kinase inhibitor in the treatment of advanced renal cell carcinoma, the therapeutic efficacy and safety of various tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma were reviewed, and the current research status of tyrosine kinase inhibitor in the treatment of advanced renal cell carcinoma was discussed. In order to better help clinicians to develop treatment plans.
【學(xué)位授予單位】：重慶醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R737.11

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 張永貞;楊國慶;王新正;郭雪蓉;陳萬青;張思維;鄭榮壽;蘇芳;;2003～2007年中國腎及泌尿系統(tǒng)其他癌發(fā)病分析[J];中國腫瘤;2012年08期

本文編號：2065248